Chinese ophthalmology drugmaker best known for low-dose atropine eye drops used to slow myopia progression in children.
Chinese ophthalmology drugmaker best known for low-dose atropine eye drops used to slow myopia progression in children.
Sells through hospital eye departments and pharmacies, where the main drug is a prescription atropine eye drop that children use to slow myopia (short-sightedness). Because treatment is a long course, repeat purchases drive sales. Other ophthalmic generics go through the same channels.
In one line: A small, eye-drops-only Bausch + Lomb.
Moat: narrow (regulatory licence, brand). Early mover and approval lead in prescription low-dose atropine for pediatric myopia control.
Headquarters: Shenyang, China · Employees: 2,396
Size Shenyang Xingqi Pharmaceutical (300573.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.83B, the 1263rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥34.79 on 18 Nov 2026.
Performance Over six months the shares fell 24.8%, against -4.7% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 16.6% over the last twelve months (peer median +7.8%); the operating margin is 32.9% (peer median 12.7%).
Valuation It trades at 13.0× forward earnings against a peer median of 18.9× (6th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +29%, so the hurdle is -24 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 33.1 points above its cost of capital (9.4% WACC).
Next results Next results expected around 22 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.81B | CN¥2.45B | CN¥1.92B | CN¥1.46B | CN¥1.24B |
| Revenue growth | — | +27% | +32% | +18% | — |
| Gross profit | CN¥2.37B | CN¥1.94B | CN¥1.47B | CN¥1.09B | CN¥950M |
| EBITDA | n/a | CN¥920M | CN¥513M | CN¥349M | CN¥304M |
| Net income | CN¥802M | CN¥696M | CN¥338M | CN¥240M | CN¥212M |
| Free cash flow | CN¥614M | CN¥483M | CN¥218M | CN¥55.6M | -CN¥13.0M |
| Capital expenditure | CN¥277M | CN¥271M | CN¥199M | CN¥262M | CN¥299M |
| Total debt | CN¥106M | CN¥101M | CN¥232M | CN¥91.1M | CN¥26.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shenyang Xingqi Pharmaceutical 300573.SZ | $1.83B | -25% | +17% | 33% | 13.0× | 5.4% |
| Santen Pharmaceutical 4536.T | $4.14B | +10% | +2% | 16% | 16.7× | -5.0% |
| Alcon ALC.SW | $36.9B | +18% | +1% | 12% | 21.5× | 12.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300573.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.5% | +0.1% | 9th highest of 21 |
| 6-month return | -24.8% | -4.7% | 3rd lowest of 21 |
| Distance from 52-week high | -41.0% | -28.3% | 6th lowest of 21 |
| Revenue growth (TTM) | +16.6% | +7.8% | 5th highest of 21 |
| Operating margin | 32.9% | 12.7% | 2nd highest of 21 |
| Forward P/E | 13.0× | 18.9× | 6th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | 5.4% | 1.2% | 6th most demanding of 14 |
| Growth delivered (Del g) | +29.1% | +7.8% | 2nd highest of 14 |
| Hurdle (Req g minus delivered) | -23.7 pp | -11.4 pp | 2nd least demanding of 14 |
| ROIC minus cost of capital | +33.1 pp | +0.7 pp | 3rd highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.83B | -25% | +17% | 33% | 13.0× | 5.4% | +29.1% |
| Guobang Pharma 605507.SS | China | $1.82B | -6% | +3% | 12% | 15.7× | -6.0% | +7.4% |
| China National Accord Medicines 000028.SZ | China | $1.81B | -3% | 0% | 2% | 10.8× | -9.5% | +4.2% |
| Zymeworks ZYME | United States | $1.81B | +5% | +98% | 17% | 160.4× | n/a | n/a |
| Dermapharm DMP.DE | Germany | $1.85B | -29% | +2% | 21% | 13.2× | -3.4% | +8.0% |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $1.85B | -38% | +5% | -18% | n/a | n/a | n/a |
| Ultragenyx Pharmaceutical RARE | United States | $1.81B | -24% | +16% | -64% | 9.6× | n/a | n/a |
| Qingdao Baheal Medical 301015.SZ | China | $1.81B | +2% | -6% | 8% | 21.0× | 10.1% | +5.0% |
| Shenzhen Hepalink Pharmaceutical 002399.SZ | China | $1.80B | -12% | -6% | 8% | 25.8× | -0.7% | +0.5% |
| United Laboratories International 3933.HK | Hong Kong | $1.80B | -20% | -13% | 5% | 13.0× | 1.2% | +7.8% |
| Cohance Lifesciences COHANCE.NS | India | $1.87B | +7% | +14% | 2% | 96.3× | n/a | n/a |
| Eton Pharmaceuticals ETON | United States | $1.79B | +226% | +101% | 29% | 24.6× | 21.9% | +359.6% |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 12.5× | -1.2% | +16.7% |
| Harbin Pharmaceutical 600664.SS | China | $1.78B | +32% | +2% | 5% | 19.7× | -5.3% | +8.2% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 18.1× | 8.0% | +9.3% |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% | +2.4% |
| Agios Pharmaceuticals AGIO | United States | $1.78B | +4% | +214% | -298% | n/a | n/a | n/a |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 54.3× | n/a | n/a |
| Grand Pharmaceutical 0512.HK | Hong Kong | $1.93B | -25% | +7% | 13% | 9.4× | 1.2% | +14.1% |
| Tsumura & 4540.T | Japan | $1.93B | +6% | +13% | 18% | 10.4× | n/a | n/a |